



Patient Details

Name : Mohd Koneen

Age / Gender : 7 Years / Male.

Father's Name : Zaheer Ahmad

Address : Bareilly, UP

- 2%. Betadine gargle
- Sitz bath
- Personal Hygiene
- Thermometer
- blood Donation
- Accommodation
- Diet
- Dangee Singh
- Sick Card

POC / PCSC No.: 219/26

Diagnosis: HL

Remarks :

PICC Line Care

अगर आपके बच्चे को PICC Line Care लगी हुई है तो डे केयर के डाक्टर या नर्स से जरूर संपर्क करें।

HIV Status..... Neg

BV 0.....1.....2.....

Omm

2. PR

give 2 more cycles, evaluate and consider for

- (i) if residual disease is localized e.g. single lymph node consider involved field RT to the residual disease.
- (ii) if residual disease is more than one site or to visceral site (s) then consider high dose Chemotherapy followed by stem cell transplant.

3. No response or Progressive disease

Review histopathology and consider high dose chemotherapy followed by stem cell transplant

RE-ASSESSMENT:

At the end of 3-4 cycles

- (i) Detailed physical examination to look for any lymph node, liver or spleen enlargement. Any new lymph node should be taken as suspicious and do FANC or biopsy to confirm or rule out disease.
- (ii) Repeat CT scan abdomen and pelvis or other site, which ever was abnormal at initial diagnosis, to document CR.
- (iii) Repeat BM biopsy where ever abnormal initially and in the cases with no response or progressive disease.

PET Scan

Positive predictive value of PET has not been validated for routine clinical use. It varies by about 60% indicating that in some instances only half of the patients will experience treatment failure in future.

Single center studies have demonstrated that PET has a negative predictive value ranging from 85% to 100% which indicates that patients with a negative PET result will not suffer from a relapse in most instances

CHEMOTHERAPY SCHEDULES

ABVD

Inj Doxorubicin/ Adriamycin	25mg/m ² IV	day 1 & 15
Inj. Bleomycin	10 mg/m ² IV	day 1 and 15
Inj. Vinblastine	6mg/m ² IV	day 1 and 15
Inj. Dacarbazine	375mg/m ² IV	day 1 and 15
Inj Dexamethasone	0.15 mg/kg	day 1 and 15

Injection Emset as required.

Off therapy from day 16-28

Repeat on day 28.



अखिल भारतीय आयुर्विज्ञान संस्थान, नई दिल्ली
ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW DELHI
Department Of Lab Medicine (Emergency and Ward)

UHID: 109120076
Patient Name : Mr MOHD KONEN
Age : 7 years 8 months 28 days
Unit Name : Unit-I
Lab Name : Lab Medicine
Reg Date : 05/05/2026 07:40 AM
Report Generated Date: 05/08/2026 06:23 am
Recommended By: Dr. Rakesh Yadav Emergency HOD

Sex : Male
Sample Received Date : 05/08/2026 05:27 AM
Department : DEPT. OF EMERGENCY MEDICINE
Unit Incharge : Dr. Rakesh Yadav
Lab Sub Centre:
Sample Collection Date: 05/08/2026 02:10 AM
Dept / IRCH No: 20260300089750
Lab Reference No: 0125

Sample Details : WC-0508260175

Report

Test Name	Result	Comment	Normal Range
Urea (Urease method)	34.7 mg/dL		• 19 - 42 mg/dL
Creatinine Enzymatic (Creatine amidinohydrolase)	0.74 mg/dL		• 0.66 - 1.25 mg/dL
Uric Acid (Uricase Colorimetric)	3.5 mg/dL		• 3.5 - 8.5 mg/dL
Calcium (Arsenazo III)	7.3 mg/dL		• 8.4 - 10.2 mg/dL
Inorganic Phosphorus (p-methylaminophenol sulfate)	3.0 mg/dL		• 2.5 - 4.5 mg/dL
Sodium (Potentiometric ISE Direct)	124 mmol/L		• 137 - 145 mmol/L
Potassium (Potentiometric ISE Direct)	3.0 mmol/L		• 3.5 - 5.1 mmol/L
Chloride (Direct ISE)	98 mmol/L		• 98 - 106 mmol/L
Total Bilirubin (Modified diazo method)	0.57 mg/dL		• 0 - 1 mg/dL
Direct Bilirubin (Calculated)	0.28 mg/dL		• 0 - 0.6 mg/dL • 0 - 0.3
Bilirubin Unconjugated (Caffeine with dual wavelength)	0.29 mg/dL		• 0.6 - 10.5 mg/dL • 0 - 1.1 • 0.6 - 10.5
Alanine Amino Transferase (ALT) (UV with P5P)	52 U/L		• 0 - 50 U/L
Aspartate Amino Transferase (AST) (IFCC with P5P)	163 U/L		• 14 - 36 U/L
Alkaline Phosphatase (ALP) (PNPP, AMP buffer-IFCC)	89 U/L		• 38 - 126 U/L • 153 - 367 U/L
Albumin (Bromocresol Green, BCG)	2.9 gm/dl		• 3.5 - 5 gm/dl
Globulin (Calculated)	2.6 gm/dl		• 3 - 3.7 gm/dl
A/G ratio (Calculated)	1.12		• 0.8 - 2
Total Protein (Biuret Method)	5.5 g/dl		• 6.3 - 8.2 g/dl

Over All Comment :

Authorised Signatory

Verified By



अखिल भारतीय आयुर्विज्ञान संस्थान, नई दिल्ली
ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW
DELHI
Department Of Lab Medicine (Emergency and Ward)



ID:
Patient Name : 109120076
Sex : Mr MOHD KONEN
Department : Male
Unit Incharge : DEPT. OF EMERGENCY
Lab Name : MEDICINE
Sub Centre : Dr. Rakesh Yadav
Lab Medicine
Dept / IRCH No: 20260030010573
Lab Reference No: 0125
Reg Date : 05/05/2026 07:40 AM
Age : 7 years 8 months 28 days
Unit Name : Unit-I
Sample Collection Date: 05/08/2026 02:10 AM
Sample Received Date : 05/08/2026 05:27 AM
Recommended By: Dr. Rakesh Yadav Emergency
HOD

Sample Details : WC-0508260175 (Serum) / Report Date: 05/08/2026 06:23 am

Test Name(Methodology)	Result	UOM	Biological Reference	Verification Comment(s)
Calcium (Arsenazo III)	7.3	mg/dL	• 8.40-10.20	
Chloride (Direct ISE)	98	mmo/L	• 98.00-106.00	
Creatinine Enzymatic (Creatine amidinohydrolase)	0.74	mg/dL	• 0.66 - 1.25 mg/dL	
Phosphorus (p-methylaminophenol sulfate)	3.0	mg/dL	• 2.50-4.50	
Potassium (Potentiometric ISE Direct)	3.6	mmo/L	• 3.50-5.10	
Sodium (Potentiometric ISE Direct)	124	mmo/L	• 137.00-145.00	
Urea (Urease method)	34.7	mg/dL	• 19.00-42.00	
Uric Acid (Uricase Colorimetric)	3.5	mg/dL	• 3.5 - 8.5 mg/dL	
A/G ratio (Calculated)	1.12		• 0.80-2.00	
Alanine Amino Transferase (ALT) (UV with P5P)	52	U/L	• 0 - 50 U/L	
Albumin (Bromocresol Green,BCG)	2.9	gm/dl	• 3.50-5.00	
Alkaline Phosphatase (ALP) (PNPP, AMP buffer-IFCC)	89	U/L	• 40.00-129.00	
Aspartate Amino Transferase (AST) (IFCC with P5P)	163	U/L	• 14 - 36 U/L	
Bilirubin Unconjugated (Caffeine with dual wavelength)	0.29	mg/dL	• 0.10-1.10	
Direct Bilirubin (Calculated)	0.28	mg/dL	• 0.00-0.30	
Globulin (Calculated)	2.6	gm/dl	• 3.00-3.70	
Total Bilirubin (Modified diazo method)	0.57	mg/dL	• 0 - 1 mg/dL	
Total Protein (Biuret Method)	5.5	g/dL	• 6.30-8.20	

Overall Comment :

Hematology Analysis Report

First Name: **MD KONEN**
 Gender: **Male**
 Department:
 Mode: **AL-WB-CD**
 Serial No.: **TW-25002239**
 Diagnosis:





Last Name:
 Age: **7Year(s)**
 Bed No.:
 Date of Birth:

Sample ID: **N.260**
 Patient ID: **109120076**
 Date of Analysis: **04-08-2026 01:48**
 Ward:
 Tube Pos.: **1-2**

Para.	Result	Unit	Ref. Ranges
1 WBC	0.76	10⁹/L	4.00 - 12.00
2 Neu#	0.32	10⁹/L	2.00 - 8.00
3 Lym#	0.39	10⁹/L	0.80 - 7.00
4 Mon#	0.04	10 ⁹ /L	0.12 - 1.20
5 Eos#	0.01	10 ⁹ /L	0.02 - 0.80
6 Bas#	0.00	10 ⁹ /L	0.00 - 0.10
7 IMG#	0.01	10 ⁹ /L	0.00 - 999.99
8 Neu%	42.0	%	50.0 - 70.0
9 Lym%	51.3	%	20.0 - 60.0
10 Mon%	5.3	%	3.0 - 12.0
11 Eos%	1.2	%	0.5 - 5.0
12 Bas%	0.2	%	0.0 - 1.0
13 IMG%	1.6	%	0.0 - 100.0
14 RBC	4.61	10 ¹² /L	3.50 - 5.20
15 HGB	10.9	g/dL	12.0 - 16.0
16 HCT	36.1	%	35.0 - 49.0
17 MCV	78.4	fL	80.0 - 100.0
18 MCH	23.7	pg	27.0 - 34.0
19 MCHC	302	g/L	310 - 370
20 RDW-CV	14.2	%	11.0 - 16.0
21 RDW-SD	41.7	fL	35.0 - 56.0
22 PLT	151	10 ⁹ /L	150 - 450
23 MPV	13.6	fL	6.5 - 12.0
24 PDW	16.1		15.0 - 17.0
25 PCT	0.205	%	0.108 - 0.282
26 P-LCC	76	10 ⁹ /L	30 - 90
27 P-LCR	50.4	%	11.0 - 45.0
28 NRBC#	0.000	10 ⁹ /L	
29 NRBC%	0.00	/100WBC	
* 30 HFC#	0.01	10 ⁹ /L	

Flag
 Lymphopenia
 Neutropenia
 Leukocytopenia

Handwritten notes: **760**, **320**, **10.9**, **1.52**



~~Adv~~ And continue with ABVD from cycle 2
onwards

Adv/ [Daily daycare followup]

CBC, LFT, RFT (SmartLab)

SYP. OMNACORTIL FORTE (5ml/15mg) 6ml PO BD.


(Taper after 2 weeks).

Take date for ABVD 15/8/26

~~19/8/26~~

N/V — OPD — 19/8/26)

[Check Clinical status


Dr. Rakesh
(prior to chemo!)

11/8/26

CDL stage III A+S.

Post #1 Nino-APD $\leftarrow$ 317
17/7

Due for #2a. today $\rightarrow$ p12
postpone

ANC = 520

Rest OK.

Bp - 96/64 mmHg

12/8/26

- No Mouth ulcer
- 2x. betadine gargles
- Sit's bath
- on sepsen
- C/O weakness.

11.1 $\rightarrow$ $\frac{8400}{1030}$ $\leftarrow$ 270L. (10/8/26)

Adv.

- NWC fresh CSE on.
5/8/26
to give next #

Q

HR 95 6/m SpO₂ 98.1.

No fresh complaint

RBS $\leftarrow$ 110 mg/dl

Diagnostic Work UP & Risk Stratification

Presenting complaints :

gradually progressive painless
enlarged nodes x 14 months

B symptoms (-)

Examination

Multiple firm enlarged nodes

Evaluation

LN Biopsy : Polymorphic population of cells comprising histiocytes, multiple lymphocytes, plasma cells, eosinophils, interspersed Hodgkin & cells
(Accession no.) Date : 15/6/16
S2632740

PEI - C1 : Metabolically active L cells
(ADG 41948/26) lymphocytes & eosinophils
(16/6/26) LSC focal involvement of spleen
CD15+ / CD30+ / EBV-LMP+ /
CD20 patchy heterozygous / CD30-

CHIP score : B symptoms (-)
Mediastinal (-)
Albumin : 4.5
Stage IV : (-)

HIV, HBs Ag, anti HCV. →

Mantoux test

Name of treatment protocol

Classical HL stage IIA
+S

Nivo - AVD

(trial patient)

Intervention arm